[go: up one dir, main page]

AR049658A2 - Ritonavir amorfo, su uso en la fabricacion de un medicamento, composicion farmaceutica, proceso para su preparacion y proceso para la preparacion de la forma polimorfa cristalina i de ritonavir. - Google Patents

Ritonavir amorfo, su uso en la fabricacion de un medicamento, composicion farmaceutica, proceso para su preparacion y proceso para la preparacion de la forma polimorfa cristalina i de ritonavir.

Info

Publication number
AR049658A2
AR049658A2 ARP050102703A AR049658A2 AR 049658 A2 AR049658 A2 AR 049658A2 AR P050102703 A ARP050102703 A AR P050102703A AR 049658 A2 AR049658 A2 AR 049658A2
Authority
AR
Argentina
Prior art keywords
ritonavir
preparation
crystalline
amino
amorfo
Prior art date
Application number
Other languages
English (en)
Inventor
J Bauer
P Bauer
S Chemburkar
A Saleki-Gerhardt
K Patel
K Allen
B Narayanan
H Spiwek
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26817251&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR049658(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of AR049658A2 publication Critical patent/AR049658A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Forma amorfa de (2S, 3S, 5S)-5-(N-(N-metil-N-((2-isopropil-4-tiazolil)metil)amino)carbonil)-L-valinil)amino)-2-(N-((5-tiazolil)metoxicarbonil)amino-1,6-difenil-3-hidroxihexano (ritonavir), su uso en la preparacion de medicamentos utiles para tratar infecciones por VIH, composiciones farmacéuticas que comprenden dicho compuesto polimorfo y el proceso para preparar dicho compuesto a partir de la Forma I del mismo. Asimismo se describe un proceso para la preparacion de la Forma polimorfa cristalina I de ritonavir de una pureza mayor al 90%. Reivindicacion 20: Un proceso para la preparacion de la Forma polimorfa cristalina I de ritonavir de pureza mayor al 90%, caracterizado porque comprende: (a) la disolucion de la Forma cristalina II de ritonavir en acetato de etilo con calentamiento a una concentracion de alrededor de 1 Kg de ritonavir / 4 L de acetato de etilo; (b) la adicion de la solucion caliente de la Forma cristalina II de ritonavir del paso (a) a una pasta fluida de nucleos cristalinos de la Forma polimorfa cristalina I de ritonavir en heptano; y (c) el enfriamineto de la mezcla resultante a alrededor de 20 degree C:
ARP050102703 1998-07-20 2005-06-29 Ritonavir amorfo, su uso en la fabricacion de un medicamento, composicion farmaceutica, proceso para su preparacion y proceso para la preparacion de la forma polimorfa cristalina i de ritonavir. AR049658A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11934598A 1998-07-20 1998-07-20
US32609399A 1999-06-04 1999-06-04

Publications (1)

Publication Number Publication Date
AR049658A2 true AR049658A2 (es) 2006-08-23

Family

ID=26817251

Family Applications (5)

Application Number Title Priority Date Filing Date
ARP990103557 AR019431A1 (es) 1998-07-20 1999-07-20 POLIMORFO CRISTALINO DE (2S,3S,5S)-5-(N-(N-((N-METIL -N- ((2-ISOPROPIL-4-TIAZOLIL)METIL) AMINO)CARBONIL)-L-VALINIL)AMINO)-2-(N-((5-TIAZOLIL) METOXICARBONIL) AMINO-1,6-DIFENIL-3-HIDROXIHEXANO Y PROCESO PARA SU PREPARACIoN.
ARP040101329 AR044029A2 (es) 1998-07-20 2004-04-20 Ritonavir amorfo, procesos para su preparacion y procesos para la preparacion de la forma polimorfa cristalina i de ritonavir sustancialmente pura
ARP050102703 AR049658A2 (es) 1998-07-20 2005-06-29 Ritonavir amorfo, su uso en la fabricacion de un medicamento, composicion farmaceutica, proceso para su preparacion y proceso para la preparacion de la forma polimorfa cristalina i de ritonavir.
ARP070100929 AR059764A2 (es) 1998-07-20 2007-03-06 Proceso para preparar una composicion farmaceutica de ritonavir y composicion que se obtiene
ARP070100928 AR059763A2 (es) 1998-07-20 2007-03-06 Proceso para la preparacion de la forma polimorfa cristalina i de ritonavir

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ARP990103557 AR019431A1 (es) 1998-07-20 1999-07-20 POLIMORFO CRISTALINO DE (2S,3S,5S)-5-(N-(N-((N-METIL -N- ((2-ISOPROPIL-4-TIAZOLIL)METIL) AMINO)CARBONIL)-L-VALINIL)AMINO)-2-(N-((5-TIAZOLIL) METOXICARBONIL) AMINO-1,6-DIFENIL-3-HIDROXIHEXANO Y PROCESO PARA SU PREPARACIoN.
ARP040101329 AR044029A2 (es) 1998-07-20 2004-04-20 Ritonavir amorfo, procesos para su preparacion y procesos para la preparacion de la forma polimorfa cristalina i de ritonavir sustancialmente pura

Family Applications After (2)

Application Number Title Priority Date Filing Date
ARP070100929 AR059764A2 (es) 1998-07-20 2007-03-06 Proceso para preparar una composicion farmaceutica de ritonavir y composicion que se obtiene
ARP070100928 AR059763A2 (es) 1998-07-20 2007-03-06 Proceso para la preparacion de la forma polimorfa cristalina i de ritonavir

Country Status (30)

Country Link
EP (4) EP1418174B1 (es)
JP (4) JP4815050B2 (es)
KR (3) KR100853371B1 (es)
CN (5) CN1502613A (es)
AR (5) AR019431A1 (es)
AT (3) ATE261947T1 (es)
AU (1) AU768207B2 (es)
BG (4) BG65150B1 (es)
BR (1) BR9912010A (es)
CA (3) CA2510949C (es)
CO (1) CO5090830A1 (es)
CY (2) CY1111600T1 (es)
CZ (2) CZ307116B6 (es)
DE (2) DE69915628T2 (es)
DK (3) DK2017269T3 (es)
ES (3) ES2214038T3 (es)
HK (2) HK1037918A1 (es)
HU (3) HU227540B1 (es)
ID (1) ID27996A (es)
IL (4) IL140492A0 (es)
MY (2) MY145265A (es)
NO (2) NO318385B1 (es)
NZ (2) NZ509125A (es)
PL (2) PL213978B1 (es)
PT (3) PT1418174E (es)
SI (3) SI1418174T1 (es)
SK (3) SK287586B6 (es)
TR (1) TR200100171T2 (es)
TW (3) TWI362382B (es)
WO (1) WO2000004016A2 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6894171B1 (en) 1998-07-20 2005-05-17 Abbott Laboratories Polymorph of a pharmaceutical
MY145265A (en) * 1998-07-20 2012-01-13 Abbott Lab Amorphous ritonavir
EP1183026B1 (en) * 1999-06-04 2006-07-05 Abbott Laboratories Improved pharmaceutical formulations comprising ritonavir
EP1395249A1 (en) * 2001-05-25 2004-03-10 Abbott Laboratories Soft elastic capsules comprising ritonavir and/or lopinavir
TWI286476B (en) * 2001-12-12 2007-09-11 Tibotec Pharm Ltd Combination of cytochrome P450 dependent protease inhibitors
US7205413B2 (en) 2002-05-03 2007-04-17 Transform Pharmaceuticals, Inc. Solvates and polymorphs of ritonavir and methods of making and using the same
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
BRPI0401742B8 (pt) 2004-05-13 2021-05-25 Cristalia Produtos Quim Farmaceuticos Ltda composto análogo do ritonavir útil como inibidor de protease retroviral, preparação do composto análogo do ritonavir e composição farmacêutica do composto análogo do ritonavir
EP1891027A1 (en) * 2005-05-30 2008-02-27 Ranbaxy Laboratories Limited Processes for the preparation of stable polymorphic form i of ritonavir
US20100099885A1 (en) * 2006-10-03 2010-04-22 Mukesh Kumar Sharma Process for the preparation of form i and form ii of ritonavir
CN102898398B (zh) * 2011-07-27 2015-01-14 上海迪赛诺药业有限公司 一种制备i型利托那韦多晶型结晶的方法
EP2822553B1 (en) 2012-03-07 2016-05-18 ratiopharm GmbH Dosage form comprising non-crystalline lopinavir and crystalline ritonavir
US9370578B2 (en) 2012-03-07 2016-06-21 Ratiopharm Gmbh Dosage form comprising lopinavir and ritonavir
CA2918707A1 (en) 2013-08-29 2015-03-05 Teva Pharmaceuticals Industries Ltd. Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir and a monolithic tablet comprising darunavir and ritonavir
WO2015155673A1 (en) 2014-04-08 2015-10-15 Teva Pharmaceutical Industries Ltd Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir
CN106749085B (zh) * 2016-12-23 2019-05-24 东北制药集团股份有限公司 一种制备利托那韦的方法
EP3569225A1 (en) 2018-05-18 2019-11-20 Pharmaceutical Oriented Services Ltd Solid dispersion containing ritonavir
RU2759544C1 (ru) * 2021-01-29 2021-11-15 Общество с ограниченной ответственностью "АМЕДАРТ" Твёрдая фармацевтическая композиция для изготовления перорального терапевтического средства для профилактики и/или лечения ВИЧ-инфекции

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5539122A (en) * 1989-05-23 1996-07-23 Abbott Laboratories Retroviral protease inhibiting compounds
US5354866A (en) 1989-05-23 1994-10-11 Abbott Laboratories Retroviral protease inhibiting compounds
DK1090914T3 (da) * 1992-12-29 2003-04-22 Abbott Lab Forbindelser, der inhiberer retroviral protease
IL110752A (en) 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
US5559158A (en) * 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
US5491253A (en) 1993-10-22 1996-02-13 Abbott Laboratories Process for the preparation of a substituted 2,5-diamino-3-hydroxyhexane
IL111991A (en) 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
US5567823A (en) * 1995-06-06 1996-10-22 Abbott Laboratories Process for the preparation of an HIV protease inhibiting compound
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US6160122A (en) 1996-06-28 2000-12-12 Abbott Laboratories Process for the preparation of a disubstituted thiazole
ZA9710071B (en) 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.
MY145265A (en) * 1998-07-20 2012-01-13 Abbott Lab Amorphous ritonavir
DE19856432A1 (de) * 1998-12-08 2000-06-15 Basf Ag Nanopartikuläre Kern-Schale Systeme sowie deren Verwendung in pharmazeutischen und kosmetischen Zubereitungen
EP1183026B1 (en) * 1999-06-04 2006-07-05 Abbott Laboratories Improved pharmaceutical formulations comprising ritonavir

Also Published As

Publication number Publication date
KR100793046B1 (ko) 2008-01-10
CA2674800A1 (en) 2000-01-27
PT2017269E (pt) 2011-12-20
BR9912010A (pt) 2001-04-10
CN1310715B (zh) 2010-11-03
JP4815050B2 (ja) 2011-11-16
PT1418174E (pt) 2009-06-08
EP2298751A2 (en) 2011-03-23
WO2000004016A3 (en) 2000-03-30
SK922001A3 (en) 2001-07-10
TWI271400B (en) 2007-01-21
SI1097148T1 (en) 2004-10-31
MY121765A (en) 2006-02-28
NO20042393L (no) 2001-01-18
CA2510949A1 (en) 2000-01-27
NZ509125A (en) 2003-02-28
NO20010298D0 (no) 2001-01-18
CZ2001203A3 (en) 2001-05-16
CO5090830A1 (es) 2001-10-30
DK1097148T3 (da) 2004-04-26
CZ298188B6 (cs) 2007-07-18
IL191582A0 (en) 2008-12-29
CA2337846A1 (en) 2000-01-27
CN102153524A (zh) 2011-08-17
CA2510949C (en) 2009-11-17
CN1502613A (zh) 2004-06-09
JP2002520410A (ja) 2002-07-09
PL213978B1 (pl) 2013-05-31
HU227540B1 (en) 2011-08-29
DK1418174T3 (da) 2009-05-18
TR200100171T2 (tr) 2001-05-21
ES2214038T3 (es) 2004-09-01
KR20060118022A (ko) 2006-11-17
BG65150B1 (bg) 2007-04-30
BG105197A (en) 2001-10-31
ATE261947T1 (de) 2004-04-15
JP5732212B2 (ja) 2015-06-10
BG109682A (bg) 2007-03-30
ATE534636T1 (de) 2011-12-15
NZ522690A (en) 2004-04-30
CA2337846C (en) 2006-02-21
HU0800267D0 (en) 2008-06-30
ID27996A (id) 2001-05-03
TWI227713B (en) 2005-02-11
JP2014074047A (ja) 2014-04-24
EP1097148A2 (en) 2001-05-09
MY145265A (en) 2012-01-13
AR059764A2 (es) 2008-04-30
CY1112139T1 (el) 2015-11-04
CY1111600T1 (el) 2015-10-07
BG110080A (bg) 2008-11-28
BG66140B1 (bg) 2011-07-29
IL140492A (en) 2010-12-30
HU229999B1 (en) 2015-04-28
DE69915628T2 (de) 2004-08-12
PL194710B1 (pl) 2007-06-29
DE69915628D1 (en) 2004-04-22
EP2017269A3 (en) 2009-06-10
DK2017269T3 (da) 2012-03-05
CN101966180A (zh) 2011-02-09
BG65963B1 (bg) 2010-07-30
AU768207B2 (en) 2003-12-04
PT1097148E (pt) 2004-05-31
HK1037918A1 (en) 2002-02-22
HUP0103823A3 (en) 2003-05-28
SI1418174T1 (sl) 2009-08-31
KR100740796B1 (ko) 2007-07-20
HU0800266D0 (en) 2008-06-30
IL191582A (en) 2016-02-29
SK287586B6 (sk) 2011-03-04
EP1418174A3 (en) 2004-06-23
IL187181A (en) 2009-09-01
NO20010298L (no) 2001-01-18
EP2017269A9 (en) 2009-10-14
AR044029A2 (es) 2005-08-24
JP2017061475A (ja) 2017-03-30
CN101259128A (zh) 2008-09-10
SK287381B6 (sk) 2010-08-09
IL140492A0 (en) 2002-02-10
KR20040081137A (ko) 2004-09-20
DE69940616D1 (de) 2009-04-30
IL187181A0 (en) 2008-02-09
AU5003799A (en) 2000-02-07
AR019431A1 (es) 2002-02-20
EP2298751A3 (en) 2011-08-17
JP2010270135A (ja) 2010-12-02
NO318385B1 (no) 2005-03-14
EP2017269B1 (en) 2011-11-23
KR20010072003A (ko) 2001-07-31
AR059763A2 (es) 2008-04-30
EP2017269A8 (en) 2009-09-30
CZ2006533A3 (cs) 2001-05-16
NO327320B1 (no) 2009-06-08
SK286388B6 (sk) 2008-09-05
TW200716550A (en) 2007-05-01
HK1121155A1 (en) 2009-04-17
CN1310715A (zh) 2001-08-29
EP2017269A2 (en) 2009-01-21
CZ307116B6 (cs) 2018-01-24
HU230150B1 (hu) 2015-09-28
EP1418174A2 (en) 2004-05-12
ES2322759T3 (es) 2009-06-26
ES2372990T3 (es) 2012-01-30
HUP0103823A2 (hu) 2002-02-28
SI2017269T1 (sl) 2012-02-29
TWI362382B (en) 2012-04-21
EP1097148B1 (en) 2004-03-17
KR100853371B1 (ko) 2008-08-22
PL348033A1 (en) 2002-05-06
ATE425974T1 (de) 2009-04-15
WO2000004016A2 (en) 2000-01-27
EP1418174B1 (en) 2009-03-18

Similar Documents

Publication Publication Date Title
AR049658A2 (es) Ritonavir amorfo, su uso en la fabricacion de un medicamento, composicion farmaceutica, proceso para su preparacion y proceso para la preparacion de la forma polimorfa cristalina i de ritonavir.
EP2487165B1 (en) Modulators of pharmacokinetic properties of therapeutics
EP2231628B1 (en) Inhibitors of cytochrome p450
ES2601820T5 (es) Moduladores de propiedades terapéutica de las farmacocinéticas
AR006598A1 (es) "composiciones anti-fungosas, su uso en la manufactura de medicamentos y un procedimiento para su preparación"
HUP0204122A2 (hu) Dioxo-tiazolidint és hetformint tartalmazó gyógyszerkészítmény és felhasználása
HU224319B1 (hu) HIV-proteáz inhibitorokat és 12-18 szénatomos zsírsavakat tartalmazó folyékony gyógyszerkészítmények
KR930005619A (ko) 위장 질환 치료용 약제
KR960028916A (ko) 우수한 유리(遊離) 및 흡수능을 가진 플라바노리그난 제제
KR910021394A (ko) 카르복실산 유도체
TNSN00137A1 (fr) Polymorphes d'un chlorhydrate d'azo-bicyclo - 2,2,2 - oct-3-ylamine cristallins et compositions pharmaceutiques les contenant
EP1800681B1 (en) Solid pharmaceutical composition comprising the thiazolyl methyl ester of [5s-(5r*,8r*,10r*,11r*)]-10-hydroxy-2-methyl-5-(1-methylethyl)-1-[2-1(1-methylethyl)-4-thiazolyl]-3,6-dioxo-8,11-bis(phenylmethyl)-2,4,7,12-tetraazatridecan-13-oic acid and preparation method thereof
HUP9900320A3 (en) Optically active thiazolidinone derivatives, preparation thereof, pharmageutical compositions containing these compounds as active ingredients and use of thia-or oxazolidine derivatives for preparation of pharmaceutical compositions
ATE269352T1 (de) 4-benzylaminochinoline konjugate mit gallensaeure und ihre heteroanalogen, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und deren anwendung
AR033331A1 (es) Formas polimorfas de un citrato de azabiciclo [2,2,2] octan-3-amina, sus composiciones farmaceuticas, procedimiento de tratamiento y procedimiento para su produccion.
JP2001525839A (ja) 炭素環式ヌクレオシド１５９２ｕ８９を含有する抗ウイルス的組合せ
WO2022024649A1 (ja) 感冒剤及び抗ウイルス剤
PE20030098A1 (es) Capsulas elasticas blandas y composiciones de las mismas
JPWO2020222108A5 (es)
IE37288B1 (en) Pharmaceutical compositions for use in the treatment of certain respiratory diseases or conditions in prematurely born children
AU2015204378B2 (en) Modulators of pharmacokinetic properties of therapeutics
EP2487163A1 (en) Modulators of pharmacokinetic properties of therapeutics
TH5099B (th) นิวคลีโอไซด์ที่ใช้ในการรักษาโรค

Legal Events

Date Code Title Description
FC Refusal